Company Research Report: Caidya

Company Overview

• Name: Caidya

• Mission: Caidya aims to liberate clinical research by listening for understanding, thinking openly, owning the success of each project, and sharing knowledge throughout the process. The company is committed to helping bring life-changing therapies to the global community through liberated clinical research.

• Founded: The origins of Caidya trace back to the foundation of Clinipace in 2004 by Jeff Williams and Chris Porter, and the founding of dMed in 2016 by Dr. Lingshi Tan. The company was formally established as Caidya following the merger of dMed and Clinipace in 2021.

• Key People:

• Lingshi Tan, Ph.D. - Executive Chairman of the Board

• Barbara Lopez Kunz - Chief Executive Officer

• John Scott, MBA - Chief Information Officer

• Simone Brown - Senior Vice President, Operations Finance

• Yingshi Qian, MBA - Senior Vice President, Global Human Resources

• Marie Hanley, BSN - Senior Vice President, Global Quality Services

• Headquarters: Caidya operates globally with a strategic presence in 23 countries, but key announcements and operations denote a significant presence in Raleigh, North Carolina, USA.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Caidya is known for being a global, multi-therapeutic contract research organization (CRO) that provides comprehensive clinical trial services.

Products and Services

• Products and Services Offered:

• Clinical Development Expertise: Expertise throughout Phases I-IV of clinical trials, ensuring efficient and compliant clinical research execution.

• Regulatory Services: Comprehensive support for navigating the wide array of regulatory pathways across diverse therapeutic areas.

• Clinical Operations: Efficient management of study planning, start-up, and execution.

• Clinical Data Management: Data-driven decision-making support, with a focus on quality assurance.

• Biometrics and Biostatistics: Ensuring trials are set up for success with deep statistical insights.

• Medical Writing: Tailored medical writing services offering high flexibility and quality.

• Pharmacovigilance: Product safety information and reporting to maintain post-marketing licenses.

• Biometrics Services: Utilizing statistical insights to enhance clinical trials.

• Clarity: Proprietary technology synthesizing data to create a real-time overview of clinical trials.

• Key Features:

• Emphasis on personalized solutions and collaborative partnerships.

• Comprehensive service capability across a diverse array of therapeutic areas including oncology, infectious diseases, and rare diseases.

• Utilization of advanced technologies for data management and regulatory compliance.

Recent Developments

• Strategic Investment: On January 13, 2025, Caidya announced a $165 million strategic growth investment from Rubicon Founders to support organic expansion and strategic acquisitions.

• Leadership Transition: Barbara Lopez Kunz was appointed as the CEO on July 22, 2024, marking a leadership transition aimed at steering the company through its next growth phase.

• Accreditations: Caidya received the Medidata Rave TSDV Accreditation on June 12, 2024, enhancing their clinical trial efficiency and data integrity.

• Expansions:

• Caidya expanded its global presence by establishing Caidya Canada Limited and opening a new office in Toronto, reported on April 1, 2024.

• Awards: Caidya received a CRO Leadership Award on July 28, 2023, for its overall capabilities within the industry.

• Mergers and Rebranding: The rebranding to Caidya followed the merger of dMed and Clinipace in 2021, aimed at delivering more personalized solutions through shared knowledge.

This report summarizes key aspects of Caidya's operations, strategic direction, and recent developments based on the provided data. The information reflects the company's alignment with its mission to advance healthcare innovation through collaborative and efficient clinical research practices.